Is self-administered DMPA an answer to contraception access in the post-Roe era?
No Thumbnail Available
Authors
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
Consider prescribing self-administered subcutaneous depot medroxyprogesterone acetate (DMPA) for contraception instead of provider-administered DMPA. Self-administration improves contraception continuation rates without notable increases in pregnancy or adverse effects.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.